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Objective: Inﬂammatory bowel disease (IBD) is a chronic disorder involving the gastrointesti-
nal  tract. Immunosuppressive drugs are usually prescribed to treat IBD patients, and this
treatment  can lead to tuberculosis reactivation. This paper aimed to analyze tuberculin skin
test (TST) results in IBD patients at a reference center in Brazil.
Methods:  We  evaluated TST results in IBD patients using a cross-sectional study. We also
analyzed  the medical records of patients treated at a reference IBD outpatient unit where
TST  is routinely performed.
Results:  We reviewed 119 medical records of 57 (47.9%) Crohn’s disease (CD), 57 (47.9%) ulcer-
ative  colitis (UC) and 5 (4.2%) indeterminate colitis (IC) patients. The mean (SD) age was 43.5
(13.7)  years old. TST was positive in 24 (20.2%) of the patients. TST was positive in 16/57
(28.1%)  UC and 6/57 (10.5%) CD patients (prevalence ratio [PR] 2.7). Forty-one patients (34.5%)
were  taking immunosuppressive drugs (azathioprine or prednisone) at the time of the TST,
and six of these patients (14.6%) had positive test results. Two patients using inﬂiximab had
negative TST results. Thirty-ﬁve of the 41 patients (85.4%) on immunosuppressive treatment
were  anergic compared with 73.1% (57/78) of the untreated patients (PR 1.2).Conclusions: Patients with IBD have TST results similar to the general Brazilian population.
Within  the IBD population, CD patients have a lower frequency of TST positivity than UC
patients.
1
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroductionInﬂammatory bowel disease (IBD) is a chronic disorder with
three  subtypes, namely Crohn’s disease (CD), ulcerative col-
itis  (UC), and indeterminate colitis (IC). All three diseases
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Este é um artigo Open Access sob a licençaoccur throughout the world and represent a serious health
problem.  IBD patients have a compromised quality of life Jardim, Candeal, Salvador, BA 40296-200, Brazil.
and  may  develop complications. To control IBD, medicines
such  as aminosalicylates, corticosteroids, immunosuppres-
sive agents and biological therapies are prescribed during
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reatment. These drugs are provided free-of-charge by the
razilian  Health Department.2 In Brazil, the Ministry of Health
id  not routinely release anti-tumor necrosis factor (anti-TNF)
or  treating patients with UC at the time of this study.
There are nearly 70,000 new cases of tuberculosis (TB) in
razil  per year. In the state of Bahia more  than 4000 annual
ases  of the disease have been reported. Despite the slow and
onstant  decline in the incidence of TB in recent years, there
ave  been approximately 4600 deaths in the state of Bahia,
hich  is a very high number, considering that TB is relatively
imple  to diagnose, is curable, and the treatment is provided
or  free by the public health system.3 Infected patients form
ranulomas that prevent the bacillus from multiplying and
isseminating, leading to the development of latent tubercu-
osis  (LTBI). The reactivation of LTBI may  occur with the use
f  immunosuppressive therapy and presence of diseases that
ause  immune deﬁciencies.4,5 The tuberculin skin test (TST)
s  widely used as a screening tool for LTBI. Treatment is rec-
mmended  for LTBI in patients who have a TST result equal
o  or greater than 5 mm in addition to having a concurrent
isk factor, such as HIV infection, immunosuppression, con-
act  with pulmonary TB within the last two years by patients
ho  had received the bacille Calmette-Guérin (BCG) vaccine
ore  than two years previously, untreated TB with sequelae of
esions  visible on a chest X-ray or organ transplantion. Treat-
ent  is also recommended for patients with a TST result equal
o  or greater than 10 mm with the following risk factors: con-
act  with pulmonary TB within the last two years by patients
ho  had received the BCG vaccine more  than two years pre-
iously,  intravenous drug use, immunocompromise, or having
ndigenous  ancestry.6
Drugs such as corticosteroids, azathioprine and mono-
lonal  anti-TNF can cause reactivation of LTBI.7,8 The Spanish
orking  Group on Crohn’s Disease and Ulcerative Colitis
GETECCU) reported that LTBI must tracked not only in
atients  taking anti-TNF- but rather in all patients on
mmunosuppressive medication.9 Prednisone reduces activa-
ion  and proliferation of lymphocytes, inhibits the production
f  certain cytokines, such as IL-1, IL-2, IL-6, IL-11 and TNF
,  causes lymphopenia and monocytopenia, and inhibits the
ifferentiation of monocytes into macrophages. Azathioprine
an  cause leukopenia, inhibit NK and CD8+ cytotoxic T cells
nd  stimulate T cell apoptosis. Both drugs can cause anergy
n  patients and lead to false-negative TST.10 A one-month
teroid treatment at doses greater than 15 mg/day may  lead to
nergic states and false-negative TST results. Similar results
ave  been observed with an azathioprine dosage greater than
 mg/kg/day.10
This study aimed to analyze TST results in IBD patients at
 reference center in Brazil.
ethods
tudy  designhis study was  conducted in the Inﬂammatory Bowel Disease
nit  of Roberto Santos General Hospital in Salvador city. This
linic  is a reference center in the state of Bahia for IBD diag-
osis  and treatment. The study was  approved by the Ethics 1 4;1  8(1):60–64  61
Committee  of Bahia School of Medicine and Public Health,
protocol number 139/2008. This was  a cross-sectional study
carried  on by analyzing patient records under regular follow-
up  care. A total of 119 patients from January to March of 2009
were  analyzed. We evaluated the following variables: age, gen-
der, length of time experiencing symptoms, and length of
time  of IBD diagnosis when the TST was performed, IBD Mon-
treal  classiﬁcation, IBD treatment and TST and chest X-ray
results.
Patients
Patients with a clinical, radiological, endoscopic and histolog-
ical  diagnosis of IBD on regular follow-up (last visit within the
last  six months) were included in this study. We see approxi-
mately  30 patients per week in this outpatient clinic. Patients
were  excluded from the study if they had cancer, HIV infection,
or  other clinical conditions that could alter the TST results.
All  of the TST values were analyzed and classiﬁed as follows:
negative (TST less than 5 mm),  weakly positive (TST equal to
or greater than 5 mm but less than 10 mm),  or strongly reactive
(TST  equal to or greater than 10 mm).  Patients were  classiﬁed
as  positive or negative after reviewing their TST scores and
considering  the following risk factors: use of immunosuppres-
sive drugs, use of prednisone greater than 15 mg/day for at
least  one month, use of azathioprine greater than 2 mg/kg/day,
use  of anti-TNF-, chest X-ray consistent with past TB, and
diabetes  mellitus. Patients had a positive TST if the TST result
was  ≥10 mm alone or ≥5 mm with at least one of the risk fac-
tors  listed above.11 The CD and UC patients were classiﬁed
according to the Montreal classiﬁcation.12
Statistical  analysis
Data collected were entered into a database in SPSS version
16.0.  Initially, a descriptive analysis was performed on the
sample.  Given the characteristics of the study design, it was
not  possible to estimate the appropriate standard error, there-
fore,  no inferential statistics were  calculated (p-values and
conﬁdence  intervals).13 Proportions were used for categorical
variables, and means with their standard deviations were  used
for continuous variables. A comparison between the propor-
tions  was  performed using the prevalence ratio (PR).
Results
Demographic and clinical characteristics are summarized in
Table  1. The characterization of the TST according to CD and
UC  diagnosis is shown in Table 2. Three patients with penetrat-
ing  disease (50%), two patients with stricturing disease (33.3%)
and  one patient with non-stricturing and non-penetrating dis-
ease (16.7%) were TST positive.
Overall, 24 patients (20.2%) were  TST positive. The TST
induration was  less than 5 mm in 92 patients (77.3%), equal
to  or more  than 5 mm but less than 10 mm in six patients
(5%) and equal to or greater than 10 mm in 21 patients (17.6%).
Of  the 119 patients, 41 (34.5%) were taking immunosuppres-
sive drugs (azathioprine or prednisone) at the time of the TST,
and  14.6% (6/41) of these patients were TST positive. The two
62  b r a z j i n f e c t d i s . 2 0 1 4;1  8(1):60–64
Table 1 – Clinical and demographic characteristics of inﬂammatory bowel disease patients.
CD UC IC Total
n = 57 n = 57 n = 5 n = 119
Age (years)
Mean (SD) 38.3 (11.0) 48.6 (14.6) 44.2 (8.8) 43.5 (13.7)
Gender n (%)
Female  35 (61.4) 35 (61.4) 05 (100.0) 75 (63.0)
Time from diagnosis (weeks)
Mean  (SD) 56.2 (140.5) 41.1 (65.0) 51 (87.9) 48.8 (108.1)
Time since symptoms (weeks)
Mean  (SD) 72.4 (137.8) 69.8 (100.4) 53.6  (86.2) 70.4  (118.6)
Montreal classiﬁcation n (%)
*Age  at diagnosis
≤16  years 0
17–40  years 36 (63.1)
>40  years 21 (36.9)
*Location
Terminal  ileum 07 (10.7)
Colon  34 (59.6)
Ileum  and colon 15 (26.4)
Upper  gastrointestinal tract 0
Terminal  ileum + upper gastrointestinal tract 01 (1.5)
*Disease  behavior
Non-stricturing, non-penetrating 19 (33.3)
Stricturing  08 (14.0)
Penetrating 30 (52.7)
*Location
Proctitis  10 (17.5)
Left colitis 28 (49.1)
Extensive colitis 19 (33.4)CD, Crohn’s disease; UC, ulcerative colitis; IC, indeterminate colitis.
patients on inﬂiximab were both TST negative and had normal
chest  X-rays. No patients taking both drugs (prednisone and
azathioprine)  presented a TST equal to or greater than 5 mm.
Thirty-ﬁve  (85.4%) of the 41 immunosuppressed patients were
anergic compared with 57 (73.1%) of the 78 untreated patients
(PR  1.2). Seven patients received prophylactic treatment with
isoniazid  before the use of azathioprine. Of these, six patients
were  TST positive, and one patient had negative TST, but the
chest  X-ray was  suggestive of TBLI.
A chest X-ray was  performed on 93 patients. The chest X-
ray  features are summarized in Table 3.
Table 2 – Characterization of TST results and immunosuppress
UC 
n = 57 
Positive TST n (%) 16 (28.1) 
Induration of TST n (%)
TST  < 5 mm 39 (68.4) 
5 mm ≤ TST < 10 mm 04 (7.0) 
TST ≥ 10 mm 14 (24.6) 
Use of immunosuppressive therapy during TST n (%) 23 (40.4) 
CD, Crohn’s disease; UC, ulcerative colitis; IC, indeterminate colitis; PR, prDiscussion
The majority of the patients in this study were  female, which
is  consistent with the literature showing a predominance of
female  patients in the IBD population.14 Age at diagnosis of
CD  patients in our study is in line with other studies indicat-
ing  that most patients were  younger than 40 years old.15 This
study  sample had an increased frequency of penetrating dis-
ease.  The explanation for this ﬁnding is that the study was
conducted  at a reference center.
ive therapy according to inﬂammatory bowel disease.
CD IC Total
n = 57 PR n = 05 n = 119
06 (10.5) 2.7 02 (40) 24 (20.2)
50 (87.7) 0.8 03 (2.5) 92 (77.3)
02 (3.5) 2.0 0 06 (5.0)
05 (8.8) 2.8 02 (1.7) 21 (17.6)
17 (29.8) 1.3 01 (20) 41 (34.5)
evalence ratio.
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Table 3 – Chest X-ray characteristics of inﬂammatory
bowel disease patients.
Positive TST Negative TST
n (%) n (%)
Normal 20 (83.2) 66 (95.6)
Upper apex nodules 01 (4.2) 01 (1.4)
Hilar thickness 01 (4.2) 0
Calciﬁed nodule in hilo 01 (4.2) 02 (3.0)
Reduced peak transparency 01 (4.2) 0b r a z j i n f e c t d i
In Brazil, the Ministry of Health has reported that 5–20% of
he  general population is TST positive.16 According to these
ata,  the frequency of positive TST in the general Brazilian
opulation is similar to that encountered in our IBD patients.
he  use of immunosuppressive therapy is expected to cause
ome  degree of anergy. However, our study did obtain positive
ST  results, indicating that LTBI is present in this population.
n  another study in northeast Brazil, the prevalence of positive
ST  in patients with chronic diseases was  22%.17
Mow  et al.18 evaluated TST results from 69 IBD patients
nd demonstrated that 83% (48/69) of the patients treated
ith  corticosteroids and/or other immunosuppressive ther-
py  (excluding inﬂiximab) were  anergic compared with 43%
21/69)  of untreated patients (p < 0.002). One possible explana-
ion  for this ﬁnding is that TST is not an effective screening
ethod for patients with LTBI and IBD because IBD patients
se  immunosuppressive therapies, which can lead to anergy.
n  our study, no patients using both prednisone and azathio-
rine  were strong reactive to TST. These results reinforce the
heory  that simultaneous use of both immunosuppressive
rugs increases the risk of anergy and interferes with TST,
ausing  false-negative results.19 The frequency of anergy in
atients  on immunosuppressive therapy found in our study
as  similar to the frequency reported in previous studies. The
igh  rates of anergy found in patients not using immunosup-
ressive therapy could be related to their nutritional status or
e characteristic of IBD.
CD  patients presented a lower frequency of overall positive
ST  results and had a higher frequency of TST results less
han  5 mm compared with UC patients. However, the use of
mmunosuppressive therapy was  equivalent between CD and
C  patients. This suggests that the immunodeﬁciency in CD
atients  could inﬂuence the TST results. CD is associated with
n  imbalance of activated Treg/Th1 and Th17 cell populations.
 lack of appropriate T cell regulation or the over-production
f effector T cells may  be involved in CD development and
xacerbation.20 The abnormal function of Treg cells in CD
atients  could lead to a reduced response to delayed hypersen-
itivity.  Although the TST has some limitations, its utilization
s  a diagnostic test for TB in IBD patients is still recommended.
Chest X-rays have a sensitivity of 59–82% and speciﬁcity of
2–63%  for active TB. Furthermore, chest X-rays only demon-
trate  abnormality in 10–20% of patients with LTBI.21 However,
n  our study, chest X-rays identiﬁed LTBI in three patients who
ad a negative TST. Our data reinforce the notion that TST
lone  is insufﬁcient for the detection of LTBI. Therefore, TST
n  association with a chest X-ray and a detailed history of TB
xposure  are essential for TB screening in IBD patients.
A  study by Gomez-Reino et al.22 resulted in 3573 nega-
ive  TST results in a population of 4593 rheumatoid arthritis
atients  receiving inﬂiximab. A repeated TST in 2196 initially
egative  patients identiﬁed 168 positive patients; 8% of the
atients  initially classiﬁed as TST negative were positive on
 repeated test. In the Brazilian state of Mato Grosso do Sul,
mong  the 194 participants, 65 patients (33.5%) were  strong
PD  reactors in the ﬁrst test, and 129 were  weak reactors or
on-reactors. They underwent a second test, which revealed
hat  10 more  patients were  reactors. Hence, the booster effect
ate  was  7.8%. Repeating TST may  improve the LTBI detec-
ion  rate and could be a method for optimizing the TSTprocess.23 Some authors have recommended repeating the
TST  to increase the accuracy of the results (booster effect).
Repeated testing is recommended for patients with initial TST
results  less than 10 mm.24 It is possible that if we  repeated the
TST  in our sample, additional positive LTBI patients would
have  been identiﬁed. This possible outcome reinforces the
importance  of the TST booster concept in immunosuppressed
patients.
A new test has recently emerged as an additional oppor-
tunity  to screen for LTBI infections. The QuantiFERON
test measures a component of cell-mediated immunity in
response  to stimulation by Mycobacterium tuberculosis. This
test  quantiﬁes the production of interferon-gamma in the
blood  and was  approved by the FDA in 2001. In 2003 and
2005,  the QuantiFERON test had its use and recommenda-
tions deﬁned by the CDC in the United States.25 A study
conducted in 200826 evaluated TST and QuantiFERON efﬁ-
cacy  in patients with IBD. In contrast to QuantiFERON, TST
was  negatively inﬂuenced by immunosuppression and previ-
ous  BCG vaccinations. The authors suggested that TST must
be  replaced by QuantiFERON as a screening test for LTBI in
IBD  patients on immunosuppressive therapy. Nevertheless, a
meta-analysis showed that it remains difﬁcult to determine
superiority between the interferon-gamma release assay and
TST  because both tests are negatively affected by immunosup-
pressive therapy. Therefore, screening prior to the initiation of
immunosuppressive therapy should be considered, and it is
imperative that all patients receive screening prior to initiat-
ing  anti-TNF therapy.27 Currently, the QuantiFERON test is not
available  for population screening in Brazil.
Conclusions
In conclusion, our patients with IBD presented TST results
similar  to the results of the general Brazilian population.
CD patients had a lower frequency of positive TST than UC
patients,  which reinforced the importance of including addi-
tional  methods, such as chest X-rays or other exams, when
screening  for LTBI in this population. Additional studies are
required  to evaluate the booster effect and QuantiFERON in
IBD patients from endemic areas, considering the high risk of
disseminated  TB during treatment.
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